Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling
Authors:
- Nicole KabellaNKNicole Kabella
- Florian P. BayerFBFlorian P. Bayer
- Konstantinos StamatiouKSKonstantinos Stamatiou
- Miriam AbeleMAMiriam Abele
- Amirhossein SakhtemanASAmirhossein Sakhteman
- Yun-Chien ChangYCYun-Chien Chang
- Antje GabrielAGAntje Gabriel
- Johannes KrummJKJohannes Krumm
- Michael AignerMAMichael Aigner
- 29 July 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (897) , eadt6552
Abstract
Mutations that activate the small GTPase KRAS are a frequent genetic alteration in cancer, and drug discovery efforts have led to inhibitors that block KRAS activity. We sought to better understand oncogenic KRAS signaling and the cytostatic effects of drugs that target this system. We performed proteomic analyses to investigate changes in protein abundance and posttranslational modifications in inhibitor-treated human KRAS-mutant pancreatic (KRAS G12C and G12D) and lung cancer (KRAS G12C) cells. The inhibitors used target these mutant forms of KRAS, the downstream effectors MEK and ERK, and the upstream regulators SHP2 and SOS1. Comparisons of phosphoproteomes between cell lines revealed a core KRAS signaling signature and cell line–specific signaling networks. In all cell lines, phosphoproteomes were dominated by different degrees of autonomous, oncogenic KRAS activity. Comparison of phosphoproteomes after short and long drug exposures revealed the temporal dynamics of KRAS-MEK-ERK axis inhibition that resulted in cell cycle exit. This transition to a quiescent state occurred in the absence of substantial proteome remodeling but included broad changes in protein phosphorylation and ubiquitylation. The collective data reveal insights into oncogenic KRAS signaling, place many additional proteins into this functional context, and implicate cell cycle exit as a mechanism by which cells evade death upon KRAS signaling inhibition.Keywords
All Related Versions
This publication has 85 references indexed in Scilit:
- mTOR substrate phosphorylation in growth controlCell, 2022
- The Human Transcription FactorsCell, 2018
- A compendium of ERK targetsFEBS Letters, 2017
- MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK‐mediated HER2 phosphorylation at Thr701Molecular Oncology, 2017
- High pH Reversed-Phase Micro-Columns for Simple, Sensitive, and Efficient Fractionation of Proteome and (TMT labeled) Phosphoproteome Digests2017
- Negative feedback regulation of the ERK1/2 MAPK pathwayCellular and Molecular Life Sciences, 2016
- USP10 Regulates p53 Localization and Stability by Deubiquitinating p53Cell, 2010
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activityBiochemical and Biophysical Research Communications, 2005
- ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets‐associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation.The EMBO Journal, 1995